The molecular basis of thrombin allostery revealed by a 1.8 Å structure of the "slow" form

Structure

Volumn 11, Issue 4, 2003, Pages 469-479

  Huntington, James A ^a   Esmon, Charles T ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Allostery; Crystal; Hemostasis; Mechanism; Structure; Thrombin

Indexed keywords

CYSTEINE; FIBRINOGEN; PHENYLALANINE; PROTEIN C; SODIUM; THROMBIN; TRYPTOPHAN;

ALLOSTERISM; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DISULFIDE BOND; PRIORITY JOURNAL; REGULATORY MECHANISM; X RAY CRYSTALLOGRAPHY;

EID: 0037387204     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(03)00049-2     Document Type: Article

References (50)

1. Stubbs M.T., Bode W. A player of many parts. the spotlight falls on thrombin's structure Thromb. Res. 69:1993;1-58.
2. Esmon C.T., Owen W.G. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc. Natl. Acad. Sci. USA. 78:1981;2249-2252.
3. Hofsteenge J., Taguchi H., Stone S.R. Effect of thrombomodulin on the kinetics of the interaction of thrombin with substrates and inhibitors. Biochem. J. 237:1986;243-251.
4. Ye J., Liu L.W., Esmon C.T., Johnson A.E. The fifth and sixth growth factor-like domains of thrombomodulin bind to the anion-binding exosite of thrombin and alter its specificity. J. Biol. Chem. 267:1992;11023-11028.
5. Fuentes-Prior P., Iwanaga Y., Huber R., Pagila R., Rumennik G., Seto M., Morser J., Light D.R., Bode W. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature. 404:2000;518-525.
6. Esmon C.T. Protein C, protein S and thrombomodulin. Hirsh J., Marder V.J., Clowes A.W., George J.N. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. R.W. Colman:2001;Lippincott Williams & Wilkins, Philadelphia. 335-353.pp.
7. Griffin J.H. Blood coagulation. The thrombin paradox. Nature. 378:1995;337-338.
8. Dang O.D., Vindigni A., Di Cera E. An allosteric switch controls the procoagulant and anticoagulant activities of thrombin. Proc. Natl. Acad. Sci. USA. 92:1995;5977-5981.
9. Parry M.A., Stone S.R., Hofsteenge J., Jackman M.P. Evidence for common structural changes in thrombin induced by active-site or exosite binding. Biochem. J. 290:1993;665-670.
10. Verhamme I.M., Olson S.T., Tollefsen D.M., Bock P.E. Binding of exosite ligands to human thrombin. Re-evaluation of allosteric linkage between thrombin exosites I and II. J. Biol. Chem. 277:2002;6788-6798.
11. Wells C.M., Di Cera E. Thrombin is a Na(+)-activated enzyme. Biochemistry. 31:1992;11721-11730.
12. Schechter I., Berger A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27:1967;157-162.
13. Krishnan R., Sadler J.E., Tulinsky A. Structure of the Ser195Ala mutant of human alpha-thrombin complexed with fibrinopeptide A(7-16). evidence for residual catalytic activity Acta Crystallogr. D Biol. Crystallogr. 56:2000;406-410.
14. Skrzypczak-Jankun E., Carperos V.E., Ravichandran K.G., Tulinsky A., Westbrook M., Maraganore J.M. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J. Mol. Biol. 221:1991;1379-1393.
15. Mathews I.I., Padmanabhan K.P., Ganesh V., Tulinsky A., Ishii M., Chen J., Turck C.W., Coughlin S.R., Fenton J.W. Crystallographic structures of thrombin complexed with thrombin receptor peptides. existence of expected and novel binding modes Biochemistry. 33:1994;3266-3279.
16. Chuang Y.J., Gettins P.G., Olson S.T. Importance of the P2 glycine of antithrombin in target proteinase specificity, heparin activation, and the efficiency of proteinase trapping as revealed by a P2 gly → pro mutation. J. Biol. Chem. 274:1999;28142-28149.
17. Baglin T.P., Carrell R.W., Church F.C., Esmon C.T., Huntington J.A. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc. Natl. Acad. Sci. USA. 99:2002;11079-11084.
18. Malkowski M.G., Martin P.D., Guzik J.C., Edwards B.F. The co-crystal structure of unliganded bovine alpha-thrombin and prethrombin-2. movement of the Tyr-Pro-Pro-Trp segment and active site residues upon ligand binding Protein Sci. 6:1997;1438-1448.
19. Stubbs M.T., Oschkinat H., Mayr I., Huber R., Angliker H., Stone S.R., Bode W. The interaction of thrombin with fibrinogen. A structural basis for its specificity. Eur. J. Biochem. 206:1992;187-195.
20. Tulinsky A., Qiu X. Active site and exosite binding of alpha-thrombin. Blood Coagul. Fibrinolysis. 4:1993;305-312.
21. Le Bonniec B.F., Myles T., Johnson T., Knight C.G., Tapparelli C., Stone S.R. Characterization of the P2′ and P3′ specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis. Biochemistry. 35:1996;7114-7122.
22. Backes B.J., Harris J.L., Leonetti F., Craik C.S., Ellman J.A. Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin. Nat. Biotechnol. 18:2000;187-193.
23. Orthner C.L., Kosow D.P. Evidence that human alpha-thrombin is a monovalent cation-activated enzyme. Arch. Biochem. Biophys. 202:1980;63-75.
24. Villanueva G.B., Perret V. Effects of sodium and lithium salts on the conformation of human alpha-thrombin. Thromb. Res. 29:1983;489-498.
25. Parry M.A., Stone S.R., Hofsteenge J., Jackman M.P. Evidence for common structural changes in thrombin induced by active-site or exosite binding. Biochem. J. 290:1993;665-670.
26. Lai M.T., Di Cera E., Shafer J.A. Kinetic pathway for the slow to fast transition of thrombin. Evidence of linked ligand binding at structurally distinct domains. J. Biol. Chem. 272:1997;30275-30282.
27. Guinto E.R., Vindigni A., Ayala Y.M., Dang Q.D., Di Cera E. Identification of residues linked to the slow→fast transition of thrombin. Proc. Natl. Acad. Sci. USA. 92:1995;11185-11189.
28. Guinto E.R., Di Cera E. Critical role of W60d in thrombin allostery. Biophys. Chem. 64:1997;103-109.
29. Arosio D., Ayala Y.M., Di Cera E. Mutation of W215 compromises thrombin cleavage of fibrinogen, but not of PAR-1 or protein C. Biochemistry. 39:2000;8095-8101.
30. Blaber M., Lindstrom J.D., Gassner N., Xu J., Heinz D.W., Matthews B.W. Energetic cost and structural consequences of burying a hydroxyl group within the core of a protein determined from Ala→Ser and Val→Thr substitutions in T4 lysozyme. Biochemistry. 32:1993;11363-11373.
31. Zhang E., Tulinsky A. The molecular environment of the Na+ binding site of thrombin. Biophys. Chem. 63:1997;185-200.
32. Pineda A.O., Savvides S., Waksman G., Di Cera E. Crystal structure of the anticoagulant slow form of thrombin. J. Biol. Chem. 277:2002;40177-40180.
33. Vijayalakshmi J., Padmanabhan K.P., Mann K.G., Tulinsky A. The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin. changes accompanying activation and exosite binding to thrombin Protein Sci. 3:1994;2254-2271.
34. Wang S.X., Esmon C.T., Fletterick R.J. Crystal structure of thrombin-ecotin reveals conformational changes and extended interactions. Biochemistry. 40:2001;10038-10046.
35. van de Locht A., Bode W., Huber R., Le Bonniec B.F., Stone S.R., Esmon C.T., Stubbs M.T. The thrombin E192Q-BPTI complex reveals gross structural rearrangements. implications for the interaction with antithrombin and thrombomodulin EMBO J. 16:1997;2977-2984.
36. Di Cera E., Guinto E.R., Vindigni A., Dang Q.D., Ayala Y.M., Wuyi M., Tulinsky A. The Na+ binding site of thrombin. J. Biol. Chem. 270:1995;22089-22092.
37. Dang Q.D., Di Cera E. Residue 225 determines the Na(+)-induced allosteric regulation of catalytic activity in serine proteases. Proc. Natl. Acad. Sci. USA. 93:1996;10653-10656.
38. He X., Ye J., Esmon C.T., Rezaie A.R. Influence of Arginines 93, 97, and 101 of thrombin to its functional specificity. Biochemistry. 36:1997;8969-8976.
39. Ye J., Rezaie A.R., Esmon C.T. Glycosaminoglycan contributions to both protein C activation and thrombin inhibition involve a common arginine-rich site in thrombin that includes residues arginine 93, 97, and 101. J. Biol. Chem. 269:1994;17965-17970.
40. Sheehan J.P., Sadler J.E. Molecular mapping of the heparin-binding exosite of thrombin. Proc. Natl. Acad. Sci. USA. 91:1994;5518-5522.
41. Gruber A., Cantwell A.M., Di Cera E., Hanson S.R. The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J. Biol. Chem. 277:2002;27581-27584.
42. Griffith M.J., Noyes C.M., Church F.C. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J. Biol. Chem. 260:1985;2218-2225.
43. Leslie A.W.G. Joint CCP4 and ESF-EACMB Newsletter on Protein Crystallography Number 26. 1992;Daresbury Laboratory, Warrington, UK.
44. Vagin A., Teplyakov A. An approach to multi-copy search in molecular replacement. Acta Crystallogr. D Biol. Crystallogr. 56:2000;1622-1624.
45. Brünger A.T., Adams P.D., Clore G.M., Delano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S.et al. Crystallography and NMR system. a new software suite for macromolecular structure determination Acta Crystallogr. D Biol. Crystallogr. 54:1998;905-921.
46. Pannu N.S., Read R.J. Improved structure refinement through maximum likelihood. Acta Crystallogr. A. 52:1996;659-668.
47. McRee D.E. A visual protein crystallographic software system for X11/XView. J. Mol. Graph. 10:1992;44-46.
48. Kraulis P.J. Molscript - a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:1991;946-950.
49. Esnouf R.M. An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. J. Mol. Graph. Model. 15:1997;132.
50. Merritt E.A., Murphy M.E.P. Raster3d version 2.0 - a program for photorealistic molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 50:1994;869-873.